Introduction: Vasopressors are commonly used after aneurysmal subarachnoid hemorrhage (aSAH) to sustain cerebral pressure gradients. Yet, the relationship between vasopressors and the degree of cerebral microcirculatory support achieved remains unclear. This study aimed to explore the changes in cerebral and peripheral regional tissue oxygen saturation (rSO 2 ) as well as blood pressure (BP) before and after vasopressor infusion in patients with aSAH. Methods: Continuous noninvasive cerebral and peripheral rSO 2 was obtained using near-infrared spectroscopy for up to 14 days after aSAH. Within-subject differences in rSO 2 before and after the commencement of vasopressor infusion were analyzed controlling for Hunt and Hess grade and vasospasm. 
concentration, thus reflecting the proportion between cerebral oxygen extraction and supply. 10 A decrease in NIRS values indicates an increase in oxygen extraction or insufficient delivery, leading to cerebral ischemia. Near-infrared spectroscopy has been used in patients with intracranial injuries including aSAH to measure regional cerebral tissue oxygen saturation (rSO 2 ), as well as in healthy subjects to assess the effect of vasopressors on cerebral oxygenation. 11Y13 However, there is conflicting evidence regarding the effect of vasopressor administration on rSO 2 measured by NIRS among different patient/subject populations. In healthy volunteers, a norepinephrine infusion of 0.1 mcg/kg per minute or greater was associated with decreased frontal lobe oxygenation and internal jugular venous oxygen saturation.
14 Meanwhile, others have reported that norepinephrine infusion improved cerebral rSO 2 in patients with aSAH with impaired cerebral autoregulation. 7 Yet, the effectiveness of vasopressor infusion on improving cerebral microcirculation as assessed by cerebral tissue oxygen in the general population with aSAH remains understudied. The aim of this study was to explore the effect of vasopressor infusion on regional cerebral and peripheral rSO 2 as well as systemic blood pressure (BP) for patients diagnosed with aSAH.
Material and Methods
This was a prospective longitudinal study (R01NR014221) approved by the local institutional review board, and all patients (or surrogates) provided consent before enrollment.
Patients and Setting
This study was conducted at a comprehensive stroke and level I regional resource trauma center in Western Pennsylvania. Inclusion criteria were: aSAH within 5 days before admission, ages 21 to 75 years, and Fisher grade of higher than 1. Exclusion criteria were: mycotic aneurysm, recurrent aSAH, or chronic debilitating neurological deficit. Patients were recruited between October 18, 2014, and November 2, 2016. The diagnoses of subarachnoid hemorrhage and aneurysm rupture were confirmed by computed tomography (CT) scan and digital subtraction angiography. After eligibility criteria were confirmed, patients or their legal representatives were approached by the research team. The study procedures were explained in detail, and patients/legal representatives were given the choice to voluntarily participate in the study. Data collection started immediately after patient's approval.
This study was conducted in a high-volume medical center where treatment of aneurysms included either endovascular or surgical aneurysm obliteration. Patients were monitored in the neurovascular intensive care unit (NVICU) for up to 14 days per institutional aSAH protocol. An external ventricular drain was used for cerebrospinal fluid diversion and to intermittently monitor intracranial pressure in patients with Hunt and Hess (HH) grades 3 to 5 and/or in the presence of hydrocephalus. Oral nimodipine was used in the standard of dose 60 mg every 4 hours but then 30 mg every 2 hours if hypotensive. Vital signs were assessed continuously via bedside monitoring and charted bihourly unless patients exhibited signs of clinical deterioration, in which case, more frequent assessments were obtained.
BP Management and Monitoring
Blood pressure monitoring commenced at the time of NVICU admission. In the acute phase of care and during vasopressor infusion, BP was continuously monitored primarily via arterial catheter. Once patients stabilized, arterial catheters were discontinued and BP was monitored using a noninvasive BP cuff. All recorded BP values (invasive and noninvasive) were downloaded from the electronic medical record and used.
Per institutional aSAH care protocol, initial target systolic BP was less than 120 to 140 mm Hg before securing the aneurysm and liberalized after aneurysm repair. In patients with neurological deterioration and/or cerebral vasospasm after aneurysm repair, systolic BP was targeted at greater than 160 mm Hg or a minimum of 20 mm Hg higher than average for stay. To achieve this goal, systolic BP less than threshold was first treated with fluid optimization and then supported with vasopressor infusion to maintain systolic BP higher than the target range. The vasopressor of choice was norepinephrine, with the addition of epinephrine, phenylephrine, or vasopressin as needed to achieve the goal.
Cerebral and Peripheral rSO 2
Continuous noninvasive cerebral and peripheral rSO 2 commenced immediately after study enrollment using NIRS (INVOS Cerebral Oximeter; Somanetics, Troy, Michigan). Cerebral rSO 2 was acquired using 2 separate sensors affixed to the left and right forehead, whereas peripheral rSO 2 was obtained using a single sensor attached to either the left-or right-hand thenar eminence. Sensors remained in place until patients Lower rSO 2 is not due exclusively to vasospasm and may reflect global microcirculatory vasoconstriction.
were discharged from the NVICU or earlier if they requested sensor removal. Continuous cerebral and peripheral rSO 2 values were recorded every 5 milliseconds and then averaged on 5-minute intervals for statistical analyses.
Vasopressors
Vasopressor infusion was used for BP support as described. Vasopressors were analyzed as a time-varying variable, and each patient in the sample, all of whom received pressors at some point, had their BP and cerebral and peripheral rSO 2 data tagged as receiving or not receiving vasopressors at each rSO 2 or BP time point. The main vasopressor used was norepinephrine with a starting dose of 0.04 mcg/kg per minute, and titration was based on targeted systolic BP. Other vasopressors infused, additive to norepinephrine, were epinephrine, phenylephrine, and vasopressin.
Cerebral Vasospasm
Neurological examinations were performed bihourly or more frequently if clinical deterioration was noted. Cerebral vasospasm was assessed by digital subtraction angiography, which was performed on day 7 postbleeding or whenever patients exhibited neurological deterioration that could not be explained by CT scan, electroencephalogram, or other assessment tools. Cerebral angiography was performed and scored by an independent neurosurgeon, with a narrowing of less than 25% indicating no spasm, 25% to 75% indicating moderate spasm, and greater than 75% indicating severe spasm. Severe vasospasm was controlled for in the statistical analyses.
Statistical Analyses
Descriptive statistics and frequency distributions using IBM SPSS 24 were used to describe the sample. The sample was restricted to patients receiving vasopressor, to serve as their own controls (data during times vasopressor was not infusing) and cases (data during times when vasopressor was infusing). This withinsubject case-and-control design was used to achieve better control over extraneous variables. Comparisons of rSO 2 and BP at the times of presence or absence of vasopressor infusion were performed using means and standard deviations. To take into account for the repeated measures within each subject, we used mixed model linear regression (SAS 9.3) to test whether cerebral rSO 2 , peripheral rSO 2 , and BP (systolic, diastolic, and mean) were statistically different between vasopressor infusion time and times off pressors. Vasopressors' group assignment (on or off) was treated as a time-varying variable. All multivariate analyses were conducted while controlling for HH grade. Importantly, severe angiographic vasospasm was also controlled for in the analyses.
Results
Of 45 patients with continuous rSO 2 data, 19 (42%) received vasopressors. The mean age for those patients (n = 19) was 56.7 T 10.5 years, 84% were female, and 79% were white. Approximately, 26% of patients had HH grade 2, 48% had HH grade 3, 21% had HH grade 4, and 5% had HH grade 5. Blood pressure monitoring commenced upon admission to the NVICU, whereas rSO 2 2 . All 19 patients who received vasopressors received norepinephrine infusion (100%), of whom 2 (11%) also received epinephrine, 4 (21%) also received phenylephrine, and 6 (32%) also received vasopressin. Six of the 19 patients (32%) had severe angiographic vasospasm, whereas 5 (26%) had moderate vasospasm. The remaining 8 patients with vasopressors had no evidence of severe or moderate angiographic vasospasm.
Descriptively, the cerebral rSO 2 mean values for the total sample were greater when vasopressors were not infusing (left, 64.4 T 9.2; right, 67.2 T 9.2) than during vasopressor infusion (left, 59.7 T 7.2; right, 60.6 T 8.2). However, the peripheral rSO 2 mean values for the total sample were slightly greater during vasopressor infusion times (60.4 T 11.0) compared with times with no vasopressor infusion (58.7 T 11.6) ( Table 1) . To test whether these observed within-subject differences were statistically significant, mixed model linear regression analysis was conducted and revealed that, during vasopressor infusion times, there was significantly lower bilateral cerebral rSO 2 even after controlling for HH grade and severe angiographic vasospasm. During vasopressor infusion times, left cerebral rSO 2 was decreased by 4.4% (b = j4.4, P G . 0001) and right cerebral rSO 2 decreased by 5.5% (b = j5.5, P = .0002), whereas there was a nonsignificant increase in peripheral rSO 2 by 1.5% (b = 1.5, P = .457) ( Table 2) .
Mean values for systolic, diastolic, and mean arterial BP were greater during vasopressor infusion times (160.6 T 25.8, 79.1 T 16.2, and 106.3 T 18.6, respectively) than for times when no vasopressors were infusing (142.7 T 29.7, 70.2 T 16.7, and 93.7 T 19.3, respectively) ( Table 1 ). The analysis of mixed model linear regression showed that systolic BP was increased by 15 mm Hg (b = 15.1), diastolic BP was increased by 7.3 mm Hg (b = 7.3), and mean BP was increased by 10 mm Hg (b = 10.1) during vasopressor infusion times, also while controlling for HH grade and severe angiographic vasospasm (P = .0001) ( Table 2) .
Discussion
With patients serving as their own cases (times when vasopressors were infusing) and controls (times when vasopressors not infusing), although BP significantly increased during times of vasopressor infusion, cerebral rSO 2 significantly decreased during infusion times, even after controlling for severe vasospasm and HH grade.
It is unclear whether vasopressors contributed to further drop in cerebral rSO 2 or whether the drop in cerebral rSO 2 was due to the dynamic nature of vasospasm, but the vasopressors blunted a further decrease (ie, cerebral rSO 2 may have been worse without vasopressors). Importantly, in 8 patients with vasopressors but no evidence of cerebral vasospasm, a decrease in cerebral rSO 2 was observed during vasopressor infusion. This finding suggests that the noted depression of cerebral rSO 2 is not due exclusively to vasospasm but perhaps a direct result of global microcirculatory vasoconstriction induced by vasopressors. In contrast, there was an improvement in the peripheral saturation during the same times of vasopressor infusion, although not statistically significant.
A negative relationship between vasopressor infusion and cerebral oxygenation has been reported in the literature. In a case report by Zeiler et al, 15 2 patients with aSAH demonstrated worsening neurological examination after norepinephrine was initiated to treat delayed cerebral ischemia and then showed neurologic improvement as soon as norepinephrine was discontinued. In patients undergoing carotid endarterectomy, Sato et al 16 reported that, despite the positive effect of norepinephrine on BP, it was associated with decreased left and right frontal cerebral oxygen saturation. Important to the current study, healthy subjects who received a norepinephrine dose of 0.1 mcg/kg per minute or higher had a decrease in cerebral oxygenation as well as decreased internal jugular venous oxygen saturation.
14 In a study by Gathier et al, 17 patients with delayed cerebral ischemia were randomized to induced hypertension with norepinephrine or not, and those with norepinephrine did not display an overall improvement in cerebral blood flow by CT perfusion during infusion.
In animal experiments, norepinephrine infusion has been shown to cause vasoconstriction and a consequent decrease in oxygen saturation in the cerebral microvasculature. 18 Meybohm et al 19 conducted an experiment in which they induced hypotension in 7 piglets by withdrawing blood, after which norepinephrine infusion was initiated. The applied norepinephrine infusion did not result in a significant increase in brain tissue oxygen. In a study of sheep, norepinephrine infused at doses of up to 60 mcg/min did not change cerebral oxygen consumption. 20 Likewise, epinephrine administration to patients during cardiopulmonary resuscitation did not result in significant improvement in cerebral rSO 2 . 21 Although norepinephrine has been demonstrated in some studies to result in short-term neurologic improvement, long-term outcome improvement has yet to be demonstrated. 22, 23 Findings from the current study, as well as those from others, suggest that further study with larger samples into these seemingly disparate effects of vasopressors on cerebral and peripheral microcirculation is warranted, as well as examination of a mechanistic explanation, including the role of intact or impaired autoregulation, the ability of vasopressors to cross the blood-brain barrier, and the integrity of this barrier after aSAH. 7, 12, 24 Possibly, further study regarding vasodilatory and other inotropic agents should also be further explored, 15 to determine whether they might result in greater shortterm benefits as demonstrated by cerebral microcirculation and the long-term benefit as demonstrated by mortality, functional, and cognitive outcomes. It is also possible that both the complex mechanisms thought to be causative for vasospasm as well as genetic predisposition may warrant variable treatments across the population as well. 22, 23, 25 This study has a number of limitations. The sample size was small, albeit greater than other studies examining this question. 11, 26, 27 The small sample lends to limited variation in demographics, aneurysm treatment, and bleeding severity, leading to limited generalizability. We did not formally assess cerebral autoregulation, vasopressor dose effect, intravascular volume, or the amount of administered intravenous fluid. These variables could be examined in a larger sample to provide more insight to our findings. In addition, there are several variables that we did not control for and that might have affected rSO 2 levels such as body and head position, hemoglobin levels, temperature, and mechanical ventilation. Finally, rSO 2 measured by NIRS may be sensitive to changes in cerebral blood flow, but this is a limitation for the NIRS technology itself. Future studies will be needed to assess the effect of these potentially impactful variables.
Conclusions
In summary, patients with aSAH who were on vasopressors demonstrated increased BP but decreased rSO 2 as measured by NIRS during pressor infusion times, even while controlling for injury severity (HH grade) and severe angiographic vasospasm. The degree to which vasopressors are helpful or harmful to cerebral microcirculatory support and the dysynchrony between cerebral and peripheral microcirculatory impact requires further study.
